Potential of immunotherapy to convert a complete cytogenetic remission in chronic myelogenous leukemia to a molecular complete remission: randomized phase II study of proteinase 3 PR1 peptide mixed with montanide ISA-51 VG adjuvant and administered with GM-CSF [granulocyte macrophage colony-stimulating factors] and peginterferon alfa-2b [PEG-INTRON, Schering Corporation].

Trial Profile

Potential of immunotherapy to convert a complete cytogenetic remission in chronic myelogenous leukemia to a molecular complete remission: randomized phase II study of proteinase 3 PR1 peptide mixed with montanide ISA-51 VG adjuvant and administered with GM-CSF [granulocyte macrophage colony-stimulating factors] and peginterferon alfa-2b [PEG-INTRON, Schering Corporation].

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2014

At a glance

  • Drugs PR1 peptide vaccine (Primary) ; Imatinib; Peginterferon alfa-2b; Sargramostim
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
    • 25 Mar 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top